Asia-Pacific Continuous Bioprocessing Market

Meticulous Research a leading global market research company, published a research report titled Asia-Pacific Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), and End User (Pharmaceuticals, Biotechnology, CROs) - Forecast to 2030 . download Free sample Report Here: https://www.meticulousresearch.com/download- sample- report/cp_id=5682?utm_source=pdf&utm_medium=social+&utm_campaign=product&utm_c ontent 08-04-2024 According to this latest publication from Meticulous Research, the Asia-Pacific continuous bioprocessing market is expected to grow at a CAGR of 28.9% from 2023 to reach $181.1 million by 2030. The growth of this market is attributed to factors such as the emerging landscape of biopharmaceuticals in Asian countries, rising manufacturing and research-related outsourcing of biopharmaceuticals, expansions in CDMOs, developments in bioprocessing technologies, and growing partnerships and collaborations among market players for biopharma manufacturing. Furthermore, the shift towards bioprocessing 4.0 and the rising adoption of personalized medicines are expected to provide significant market growth opportunities. However, the limitations of continuous bioprocessing may restrain the growth of this market. Additionally, manufacturers hesitation to shift from batch manufacturing to continuous manufacturing poses challenges to the market players. Browse in depth: https://www.meticulousresearch.com/product/asia-pacific-continuous- bioprocessing-market- 5682?utm_source=pdf&utm_medium=social+&utm_campaign=product&utm_content=08- 04-2024 Key Players: The key players operating in Asia-Pacific continuous bioprocessing market are 3M Company (U.S.), Cytiva (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), Solida Biotech GmBH (Germany), Electrolab Biotech Limited (U.K.), Biowest (France), and Bionet (U.S.). Asia-Pacific Continuous Bioprocessing Market: Future Outlook Asia-Pacific continuous bioprocessing market is segmented by Product (Filtration Systems and Consumables, Chromatography Systems and Consumables, Cell Culture Media, Buffers, and Reagents, Incubators and Shakers, Bioreactors, Centrifuges, Sterilizers, and Other Instruments and Consumables), Application (Commercial Applications [Monoclonal Antibodies (mAbs) Production, Cell and Gene Therapy

Production, Vaccine Manufacturing, Plasma Fractionation, and Recombinant Protein Production], R&D), End User (Pharmaceutical and Biotechnology Companies, Contract Development and Manufacturing Organizations (CDMOS) and Contract Research Organizations (CROS), and Academic and Research Institutes), and Country. The study also evaluates industry competitors and analyzes the market at the country level. Speak to analyst: https://www.meticulousresearch.com/speak-to- analyst/cp_id=5682?utm_source=pdf&utm_medium=social+&utm_campaign=product&utm _content=08-04-2024 In 2023, among the products, the filtration systems and consumables segment is estimated to account for the largest share of the market. Filtration is commonly used in biopharmaceutical processing for separating components. It is used in various downstream operations, such as clarification, filtration of intermediates, critical final filling applications, or upstream processing for sterilizing-grade filtration of cell culture media. The highest revenue share of this segment is attributed to the recurring use of filtration at every step in bioprocessing and technological advancements in filtration technologies. In 2023, among the applications, the commercial applications segment is estimated to account for the largest share of the market. Growing initiatives supporting the adoption of biopharmaceuticals, rising outsourcing, and accelerated developments in personalized therapies are likely to enhance the demand for bioprocessing systems and consumables for the commercial bioproduction of monoclonal antibodies (mAbs), vaccines, gene therapies, and recombinant protein-based therapies; thereby drive the continuous bioprocessing market for commercial application. biopharmaceutical manufacturing Download request sample report here: https://www.meticulousresearch.com/request- sample- report/cp_id=5682?utm_source=pdf&utm_medium=social+&utm_campaign=product&utm_ content=08-04-2024 In 2023, among the end users, the pharmaceutical and biotechnology companies segment is estimated to account for the largest market share due to factors such as capacity expansions by biopharmaceutical manufacturers and the extensive adoption of biopharmaceutical processing equipment biopharmaceutical and biotechnology sectors. for bioproduction in the Geographic Review: This research report provides a comprehensive analysis of the continuous bioprocessing market in Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Indonesia, and Rest of Asia-Pacific). In 2023, China is expected to account for the largest share of the Asia-Pacific continuous bioprocessing market. The growing focus on the pharmaceutical and biopharmaceutical industry, rising

investment in biosimilars, and support initiatives for CDMOs are the factors driving the market growth. Quick Buy: https://www.meticulousresearch.com/Checkout/41500504?utm_source=pdf&utm_medium= social+&utm_campaign=product&utm_content=08-04-2024 Contact Us: Meticulous Research Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous- research